MYNZ logo

Mainz Biomed BV (MYNZ) Stock

Profile

Sector:

Healthcare

Country:

Germany

IPO:

05 November 2021

Indexes:

Not included

Description:

MYNZ (Mainz Biomed BV) is a biotechnology company focused on developing innovative diagnostic solutions for early disease detection. They specialize in molecular tests, particularly for gastrointestinal diseases, aiming to improve patient outcomes through advanced technology and personalized healthcare solutions.

Key Details

Price

$6.86

Annual Revenue

$895.50 K(+68.99% YoY)

Annual EPS

-$64.80(+12.90% YoY)

Annual ROE

-303.20%

Beta

0.41

Events Calendar

Earnings

Next earnings date:

May 15, 2025

Recent quarterly earnings:

Oct 21, 2024

Recent annual earnings:

Apr 10, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 03, 2024

Analyst ratings

Recent major analysts updates

25 Nov '24 HC Wainwright & Co.
Neutral
12 Apr '24 Cantor Fitzgerald
Neutral
06 Mar '24 HC Wainwright & Co.
Buy
21 Nov '23 Cantor Fitzgerald
Neutral
20 Nov '23 HC Wainwright & Co.
Buy
26 Sept '23 Cantor Fitzgerald
Overweight
22 Sept '23 HC Wainwright & Co.
Buy
14 Sept '23 Cantor Fitzgerald
Overweight
22 Aug '23 Cantor Fitzgerald
Overweight
18 Aug '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
MYNZ
globenewswire.com19 December 2024

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
MYNZ
globenewswire.com16 December 2024

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
MYNZ
benzinga.com03 December 2024

Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.

Mainz Biomed Announces Stock Split
Mainz Biomed Announces Stock Split
Mainz Biomed Announces Stock Split
MYNZ
globenewswire.com29 November 2024

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
MYNZ
globenewswire.com21 October 2024

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
MYNZ
globenewswire.com01 October 2024

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
MYNZ
globenewswire.com18 September 2024

BERKELEY, Calif. and MAINZ, Germany, Sept.

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
MYNZ
globenewswire.com25 July 2024

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed Provides Half Year 2024 Corporate Update
MYNZ
globenewswire.com02 July 2024

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
MYNZ
globenewswire.com03 June 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed's mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Mainz Biomed BV?
  • What is the ticker symbol for Mainz Biomed BV?
  • Does Mainz Biomed BV pay dividends?
  • What sector is Mainz Biomed BV in?
  • What industry is Mainz Biomed BV in?
  • What country is Mainz Biomed BV based in?
  • When did Mainz Biomed BV go public?
  • Is Mainz Biomed BV in the S&P 500?
  • Is Mainz Biomed BV in the NASDAQ 100?
  • Is Mainz Biomed BV in the Dow Jones?
  • When was Mainz Biomed BV's last earnings report?
  • When does Mainz Biomed BV report earnings?
  • Should I buy Mainz Biomed BV stock now?

What is the primary business of Mainz Biomed BV?

MYNZ (Mainz Biomed BV) is a biotechnology company focused on developing innovative diagnostic solutions for early disease detection. They specialize in molecular tests, particularly for gastrointestinal diseases, aiming to improve patient outcomes through advanced technology and personalized healthcare solutions.

What is the ticker symbol for Mainz Biomed BV?

The ticker symbol for Mainz Biomed BV is NASDAQ:MYNZ

Does Mainz Biomed BV pay dividends?

No, Mainz Biomed BV does not pay dividends

What sector is Mainz Biomed BV in?

Mainz Biomed BV is in the Healthcare sector

What industry is Mainz Biomed BV in?

Mainz Biomed BV is in the Diagnostics & Research industry

What country is Mainz Biomed BV based in?

Mainz Biomed BV is headquartered in Germany

When did Mainz Biomed BV go public?

Mainz Biomed BV's initial public offering (IPO) was on 05 November 2021

Is Mainz Biomed BV in the S&P 500?

No, Mainz Biomed BV is not included in the S&P 500 index

Is Mainz Biomed BV in the NASDAQ 100?

No, Mainz Biomed BV is not included in the NASDAQ 100 index

Is Mainz Biomed BV in the Dow Jones?

No, Mainz Biomed BV is not included in the Dow Jones index

When was Mainz Biomed BV's last earnings report?

Mainz Biomed BV's most recent earnings report was on 21 October 2024

When does Mainz Biomed BV report earnings?

The next expected earnings date for Mainz Biomed BV is 15 May 2025

Should I buy Mainz Biomed BV stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions